CLINICAL TRIALS PROFILE FOR LUMAKRAS
✉ Email this page to a colleague
All Clinical Trials for lumakras
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05054725 ↗ | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Recruiting | Amgen | Phase 2 | 2021-10-01 | The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC |
NCT05054725 ↗ | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Recruiting | Sanofi | Phase 2 | 2021-10-01 | The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC |
NCT05054725 ↗ | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Recruiting | Revolution Medicines, Inc. | Phase 2 | 2021-10-01 | The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for lumakras
Condition Name
Clinical Trial Locations for lumakras
Trials by Country
Clinical Trial Progress for lumakras
Clinical Trial Phase
Clinical Trial Sponsors for lumakras
Sponsor Name